Estrogen-progestin oral contraceptive and nicotine exposure synergistically confers cardio-renoprotection in female Wistar rats

Simple item page
dc.contributor.authorMichael, Olugbenga Samuel
dc.contributor.authorDibia, Chinaza
dc.contributor.authorAdeyanju, Oluwaseun
dc.contributor.authorOlaniyi, Kehinde
dc.contributor.authorAreola, Emmanuel
dc.contributor.authorOlatunji, Lawrence Aderemi
dc.date.accessioned2025-05-08T10:34:45Z
dc.date.available2025-05-08T10:34:45Z
dc.date.issued2020-06-07
dc.description.abstractApproximately fifty percent of premenopausal women who smoke cigarettes or on nicotine replacement therapy are also on hormonal contraceptives, especially oral estrogen-progestin. Oral estrogen-progestin therapy has been reported to promote insulin resistance (IR) which causes lipid influx into non-adipose tissue and impairs Na+/K+ -ATPase activity, especially in the heart and kidney. However, the effects of nicotine on excess lipid and altered Na+/K+ -ATPase activity associated with the use of estrogen-progestin therapy have not been fully elucidated. This study therefore aimed at investigating the effect of nicotine on cardiac and renal lipid influx and Na+/K+ -ATPase activity during estrogen-progestin therapy. Twenty-four female Wistar rats grouped into 4 (n = 6/group) received (p.o.) vehicle, nicotine (1.0 mg/kg) with or without estrogen-progestin steroids (1.0 μg ethinyl estradiol and 5.0 μg levonorgestrel) and estrogen-progestin only daily for 6 weeks. Data showed that estrogen-progestin treatment or nicotine exposure caused IR, hyperinsulinemia, increased cardiac and renal uric acid, malondialdehyde, triglyceride, glycogen synthase kinase-3, plasminogen activator inhibitor-1, reduced bilirubin and circulating estradiol. Estrogen-progestin treatment led to decreased cardiac Na+/K+-ATPase ac tivity while nicotine did not alter Na+/K+-ATPase activity but increased plasma and tissue cotinine. Renal Na+/K+-ATPase activity was not altered by the treatments. However, all these alterations were reversed following combined administration of oral estrogen-progestin therapy and nicotine. The present study therefore demon strates that oral estrogen-progestin therapy and nicotine exposure synergistically prevents IR-linked cardio-renotoxicity with corresponding improvement in cardiac and renal lipid accumulation, oxidative stress, in- flammation and Na+/K+-ATPase activity
dc.description.sponsorshipThis research was done without a specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
dc.identifier.citation10.Michael, O.S., Dibia, C.L., Adeyanju, O.A., Olaniyi, K.S., Areola, E.D., & Olatunji, L.A. (2020). Estrogen-progestin oral contraceptive and nicotine exposure synergistically confers cardio-renoprotection in female Wistar rats. Biomedicine and Pharmacotherapy, 129, 110387, Published by Elsevier. Available online at: Biomedicine & Pharmacotherapy | Vol 129, September 2020 | ScienceDirect.com by Elsevier
dc.identifier.uri10.1016/j.biopha.2020.110387
dc.identifier.urihttps://uilspace.unilorin.edu.ng/handle/123456789/16407
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofseries129; 110387
dc.subjectEstrogen-progestin therapy
dc.subjectCardiac
dc.subjectNa+-K+-ATPase activity
dc.subjectLipid
dc.subjectInsulin resistance
dc.subjectMetabolic stress
dc.subjectNicotine
dc.titleEstrogen-progestin oral contraceptive and nicotine exposure synergistically confers cardio-renoprotection in female Wistar rats
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Paper 10.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections